Symbiosis Pharmaceutical Services, a leading CMO specializing in sterile GMP manufacturing of biopharmaceuticals, has announced the expansion of its business development team by welcoming two seasoned US-based directors. Jacqueline Towell will head the efforts on the West Coast, while Cindy Koonce will take charge of the East Coast.
Both Jacqueline and Cindy bring extensive experience from the pharmaceutical and biotechnology industries, enhancing Symbiosis’ capacity to serve clients across North America. This move underscores the company’s dedication to offering swift, high-quality fill-finish services for biopharmaceuticals.
Jacqueline, with over a decade of experience in the CDMO sector from companies like Alcami, Patheon, and Pii, will spearhead business development and manage strategic accounts on the US West Coast from her base in Southern California.
“Leveraging my expertise in technical solutions, client management, and negotiations will be pivotal in propelling Symbiosis’ growth and affirming its standing in the burgeoning biologics market,” stated Jacqueline.
“I aim to improve Symbiosis’ capability to meet the soaring demand for superior drug manufacturing, particularly for biologics and advanced therapies. It’s an exciting era for us!”
Cindy, operating from Wilmington, NC, brings two decades of business development know-how from her tenures at Alcami, Pii, and Infinity Laboratories. In her role, she will cultivate new business prospects and manage existing partnerships on the US East Coast.
Cindy remarked: “My customer-oriented approach and in-depth industry knowledge align seamlessly with Symbiosis’ mission to deliver exceptional service and top-notch manufacturing solutions.”
These strategic appointments coincide with Symbiosis’ expansion strategy, as the company plans to launch a new state-of-the-art automated sterile facility near its current premises in Stirling, Scotland, expected to be fully operational by early 2025 post-regulatory approval. This facility will boost the company’s capabilities in commercial-scale sterile manufacturing, catering to a broader global clientele.
Colin MacKay, CEO of Symbiosis Pharmaceutical Services, stated, “The addition of Jacqueline and Cindy exemplifies our strong commitment to client support and expanding our North American market presence. Their industry prowess and success in business development will help us seize new opportunities and better serve clients in key areas, while also expanding our global capabilities.”
The growth of Symbiosis’ business development team aligns with the company’s strategic objective to enhance client relationships, stimulate business advancement, and address the growing need for GMP manufacturing services in the biopharmaceutical sector.
The Stirling facility in Scotland is tailored for biologic and small molecule pharmaceutical production, servicing global biotechnology and pharmaceutical firms requiring rapid production of sterile injectable pharmaceuticals for clinical trials and commercial supply.
With a focus on regulatory compliance, technical expertise, and operational flexibility, Symbiosis offers direct access to an expert team in life sciences, adding significant value to new drug development ventures and meeting clients’ manufacturing supply chain demands. This focus has led to sustained annual growth and the establishment of enduring client partnerships worldwide.